EGAGenomicsILLUMINA, Illumina HiSeq 2000Otherhttps://ega-archive.org/studies/EGAS00001002402EGAEGA study EGAS00001002402Whole-exome sequencing (WES) data of papillary thyroid cancer and adjacent normal tissuesEGArestrictedCarcinoma, Papillary Thyroid Cancers, Asian, thyroid papillary carcinoma, Mini Exon, papillary thyroid cancer, Thyroid Carcinoma, papillary thyroid gland carcinoma, East Asian, Papillary Carcinoma Of Thyroid, Far East, Nonmedullary Thyroid Carcinoma, School-Age, School Age, Mini-Exon, papillary carcinoma of the thyroid gland, thyroid gland papillary carcinoma, Eastern, papillary thyroid carcinoma, East, East Asian Peoples, PTC, Nonmedullary Thyroid Carcinomas, Asian People, Carcinomas, School Age Populations., study, School-Age Populations, papillary carcinoma of thyroid gland, Populations, Eastern Asian Peoples, Genomes, Papillary Thyroid Carcinomas, exonic region, Mini-Exons, Exon, Eastern Asian People, whole genome, Cancers, Population, papillary cancer of thyroid, papillary carcinoma of the thyroid, Nonmedullary, Far East Asian, Thyroid Cancers, Papillary Thyroid Carcinoma, Papillary, East Asians, papillary carcinoma of thyroid, Far East Asians, Thyroid Carcinomas, Papillary Thyroid Cancer, People, Nonmedullary Thyroid, Familial Nonmedullary Thyroid Cancer, Eastern Asians, papillary cancer of the thyroid gland, Eastern Asian, School-Age Population, School Age Population, papillary cancer of thyroid gland, Chinese, papillary cancer of the thyroid, Papillary Thyroid, Cancer, thyroid gland papillary cancertuf, Biological Markers, Viral Marker, Materials, Surrogate Endpoints, PTCH11, Clinical Markers, Laboratory, Clinical Marker, Neoplasms, MTC1, Benign Neoplasm, number, CG2411, Biochemical, Mini Exon, Endpoint, Gene, papillary thyroid cancer, Cf9, papillary thyroid gland carcinoma, Tumor, Serum, Malignant, A230106A15Rik, presence, RET-ELE1, Surrogate End Points, Mutations, Surrogate Markers, Laboratory Markers, Biological, Mini-Exon, TST1, papillary thyroid carcinoma, Ptc_Dm, average, treatment, study, Biomarker, WES, TPC, Clinical, Genetic, Malignancy, PTCH, Biological Marker, Tissue, BcDNA:RH36596, papillary cancer of thyroid, ptch, papillary carcinoma of the thyroid, genetic, Neoplasias, Conf, Immunologic Markers, Immune, Markers, malignant neoplasm, Viral Markers, disease management, Therapies, Ptc1, Malignancies, PTC1, RET51, constitutitional genetic, Immunologic Marker, papillary cancer of the thyroid, Biologic, Cancer, Tumors, RET, Therapy, Viral, Malignant Neoplasm, Surrogate Endpoint, phase transfer catalysts, Serum Markers, thyroid papillary carcinoma, familial, End Point, Biochemical Markers, Biologic Marker, Cistrons, c-Ret, Immune Marker, pat, CDHR16, count in organism, DmelCG2411, Benign, MT, HSCR1, Marker, Surrogate End Point, Ptch, Neoplasm, papillary carcinoma of the thyroid gland, Genetic Materials, CDHF12, thyroid gland papillary carcinoma, phase-transfer catalysts, HPE7, l(2)k02507, Genetic Material, PTC, Ptc, Biologic Markers, papillary carcinoma of thyroid gland, Serum Marker, primary cancer, phase transfer catalyst, End Points, exonic region, Surrogate, Mini-Exons, Endpoints, Exon, Benign Neoplasms, NBCCS, Cancers, Immunologic, MEN2A, BCNS, Laboratory Marker, mes, MEN2B, malignant tumor, Treatments, Surrogate Marker, thyroid gland papillary cancer., Malignant Neoplasms, papillary carcinoma of thyroid, rubr, Therapeutic, D10S170, Biochemical Marker, Material, H4, papillary cancer of the thyroid gland, cardinality, Cistron, Treatment, inherited genetic, dPtc, papillary cancer of thyroid gland, hereditary, Neoplasia, com4, RET9, thyroid gland papillary cancer, Immune MarkersfalseComprehensive investigation of genome architecture of papillary thyroid cancer with whole-exon sequencing in the Chinese population.In this study, we performed whole-exon sequencing (WES) of 50 paired PTC tumors and adjacent normal tissues to identify novel potential biomarkers. We extracted mutational signatures which induce somatic mutations. Moreover, we observed copy number changes frequently occurring in some cancer related genes. Our study covers a comprehensive genetic framework that can be used in clinical trials and treatment modalities in PTC.2017-08-14 10:46:42EGAS000010024029606EGAD00001003262EGAC00001000010